Global Life Sciences
Overview
Featured News & Insights
0017
Contacts
Services
Advising on the full scope of regulatory, compliance and enforcement, litigation and transactional matters, we can offer you a holistic legal approach that will smooth your path as you navigate industry changes, technological advances, market demands and policy hurdles.
Regions
From high-profile transactions to regulatory issues and complex litigation, we collaborate across borders and disciplines to help our clients in more than 70 countries face challenges and embrace opportunities.

All Professionals
sort


Capabilities
- Antitrust and Competition
- Capital Markets
- Commercial Litigation and Disputes
- Emerging Companies and Venture Capital
- Environmental, Health, and Safety
- Food, Drug and Medical Device
- Global Arbitration, Trade and Advocacy
- Government Strategies
- Healthcare
- IP Litigation
- M&A
- Privacy and Cybersecurity
- Private Equity
- Product Liability and Mass Torts
- Technology Sector
- Technology and Life Sciences Transactions
Related Resources
Related Blogs
News & Insights
Sidley's 2026 San Diego Clinical Trial SeriesThursday, January 29, 2026 | Thursday, March 12, 2026 | Tuesday, April 21, 2026U.S. Clinical Trial Design & Execution RisksThursday, January 29, 2026At the Table: Serving Up a Lively Discussion with the FDA, USDA, and HHSWednesday, January 28, 2026Delaware Supreme Court Makes Earnouts Less Risky For Buyers Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory PathwayJanuary 27, 2026
Conferences
Conferences
Seminars
GoodLifeSci
Medical Products Market Access: Favorable Advisory Opinion Reaffirms Discounting FlexibilitiesJanuary 21, 2026Top 10 FDA Areas We Are Watching For 2026January 12, 2026Impact of U.S. FDA Warning Letters in Europe: Practical Considerations for IndustryJanuary 12, 2026#DrugPricing: More Average Sales Price Proposals and New Comment PeriodJanuary 6, 2026
Global Life Sciences Update
Sidley Updates
Food, Drug, and Medical Device Update
Global Life Sciences Update
DOJ Announces Renewal of FCA Working GroupOctober 2025False Claims Act Liability: When Do Claims for Health Care Reimbursement 'Result From' Anti-Kickback Statute Violations?September 25, 2025Department of Health and Human Services Office of General Counsel Statement of Organization Suggests Potential Consolidation, Expansion of AuthoritySeptember – October 2025Meeting EU Data, Cybersecurity, and Artificial Intelligence Law Obligations: A Checklist for Swiss Life Sciences CompaniesApril 3, 2025
Pratt’s Government Contracting Law Report
Reuters
The Journal of Federal Agency Action
Publications
Sidley's 2026 San Diego Clinical Trial SeriesThursday, January 29, 2026 | Thursday, March 12, 2026 | Tuesday, April 21, 2026U.S. Clinical Trial Design & Execution RisksThursday, January 29, 2026At the Table: Serving Up a Lively Discussion with the FDA, USDA, and HHSWednesday, January 28, 2026Korea Night @ JPM 2026Wednesday, January 14, 2026
Conferences
Conferences
Seminars
Receptions
Sidley Advises on Market-Defining Cross-Border India Matters in 2025January 12, 2026Sidley Represents Smith+Nephew in Integrity Orthopaedics Acquisition Valued Up to US$450 MillionJanuary 12, 2026Sidley Represents BioRender in Investment Valuing Company at $900 MillionJanuary 2, 2026Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease TherapyDecember 18, 2025
Announcements
Announcements
Announcements
Announcements
Delaware Supreme Court Makes Earnouts Less Risky For Buyers Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory PathwayJanuary 27, 2026FY 2025 FCA Settlements and Judgments Statistics Show Highest Recoveries EverJanuary 20, 2026U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025
GoodLifeSci
Original Source
GoodLifeSci
GoodLifeSci
Regulatory Considerations for the Next Wave of Development-Stage Transactions @ JPM 2026January 12, 2026What's Ahead for Life Sciences Dealmaking @ JPM 2026January 12, 2026Top 10 FDA Areas We Are Watching @ JPM 2026January 12, 2026Renewed Market Optimism @ JPM 2026January 12, 2026
Videos
Videos
Videos
Videos






































